ArticleFrontiers in pharmacology2021
18KHT01, a Potent Anti-Obesity Polyherbal Formulation.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Impact of ashwagandha (Withania somnifera L.) supplementation on serum lipid concentrations and anthropometric parameters in adults with overweight and obesity: a double-blind, placebo-controlled pilot study.Nutrition & metabolism · 2025Article
- Network pharmacology and metabolomics reveal mathurameha, a Thai traditional Anti-Diabetic formula, enhances glucose metabolism through PI3K-AKT/AMPK/GLUT4 pathway modulation.Scientific reports · 2025Article
- Therapeutic Potential of Santa Herba Extract in Obesity: Impact on Lipid Metabolism and Hormonal Balance.Food science & nutrition · 2025Article
- Article
- Exploring the therapeutic potential ofVeterinary world · 2024Article
- Intestinal mucosal microbiota mediate amino acid metabolism involved in the gastrointestinal adaptability to cold and humid environmental stress in mice.Microbial cell factories · 2024Article
- Response surface methodology based development of an optimized polyherbal formulation and evaluation of its anti-diabetic and anti-obesity potential in high-fat diet-induced obese mice.Journal of traditional and complementary medicine · 2024Article
- Toxicological Evaluation of a Polyherbal Formulation (18KHT01) and Validation of UPLC-DAD Method for Quality Control.BioMed research international · 2024Article
- Yellow Himalayan Raspberry (Molecules (Basel, Switzerland) · 2023Review
- Anti-obesity effect of the bacterial product nisin in an NIH Swiss mouse model.Lipids in health and disease · 2023Article
- Screening of Antioxidant, Antibacterial, Anti-Adipogenic, and Anti-Inflammatory Activities of Five Selected Medicinal Plants of Nepal.Journal of experimental pharmacology · 2023Article
- Amelioration of hyperglycemia and hyperlipidemia in a high-fat diet-fed mice by supplementation of a developed optimized polyherbal formulation.3 Biotech · 2022Article
- Anti-Obesity Potential of Ponciri Fructus: Effects of Extracts, Fractions and Compounds on Adipogenesis in 3T3-L1 Preadipocytes.Molecules (Basel, Switzerland) · 2022Article
- Antiobesity Activity of Two Polyherbal Formulations in High-Fat Diet-Induced Obese C57BL/6J Mice.BioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a life-threatening metabolic disorder necessitating urgent development of safe and effective therapy. Currently, limited such therapeutic measures are available for obesity. The present study was designed to develop a novel, safe and effective herbal therapy for the management of obesity. A polyherbal formulation (18KHT01) was developed by homogeneously mixing a specific proportion of crude
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.